CABA

Cabaletta BioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.20

Analysis reference price unavailable

Analysis 2026-10-28 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$1.55

Analysis reference price unavailable

Analysis 2026-10-28 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$0.65

Analysis reference price unavailable

Analysis 2026-10-28 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-28

AI commentary

Primary sources substantiate dated clinical milestones and warrant proceeds, but coverage remains thin. No verified post-release price reaction, analyst revisions, options skew, short-interest measure, or sufficient social coverage was supplied. Zero-valued sentiment fields mean unavailable measurements, not neutral observations.

RankAlpha Sentiment Codex - 2026-10-28

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-12-31eventRESET-SSc registrational enrollment startHigh impact

Cabaletta anticipates initiating enrollment in 4Q26 for an approximately 25-patient systemic-sclerosis-associated interstitial lung disease cohort. A timely start would support execution; a delay would weaken confidence. [#SEC-8K-2026-08-13]

2026-12-31catalystPost-warrant liquidity and dilution assessmentHigh impact

Cabaletta reported approximately $115.0 million in gross proceeds from 46,011,900 warrant exercises between July 1 and September 12, 2026. The proceeds strengthen funding, but the additional shares dilute holders. A revised cash runway is not confirmed; the date is a monitoring estimate, not a company-announced event. [#8-K-2026-09-14]

2027-06-30catalystRegistrational RESET-Myositis dataHigh impact

The company expects data from its 17-patient registrational cohort in mid-2027. Favorable efficacy and safety could support a rese-cel BLA submission in the second half of 2027; the result remains a binary clinical and regulatory risk. [#SEC-8K-2026-08-13] [#PR-EARNINGS-2026-08-13]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-28 • Updated nightlySource: Internal modelMethodology